newsfilter
← Latest News
GlobeNewswire·

Rhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update

-- Strong U.S. launch momentum for IMCIVREE® (setmelanotide) for acquired hypothalamic obesity (HO) continues with more than 700 patient start forms as of September 30, 2026 ---- Third quarter 2026 net product revenue